SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

MORE HEADLINES

» Markets | Economy | Companies

- Governments Must Take Steps To Avoid More Dubais: El-Erian

PHARMA'S MARKET VIDEO

» More

Sebelius on Vaccines

24 Nov 2009

Discussing whether a new $487M investment from the government will help speed up the production of the most important vaccines, with Kathy Sebelius, Health & Human Services secretary and CNBC's Mike Huckman.

The New Formula for Faster Vaccines

24 Nov 2009

Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are faster, better and cheaper to make than egg-based methods, reports CNBC's Mike Huckman.

Novartis Opens 1st US Plant for Flu Vaccine

24 Nov 2009

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Pharma's Market

Text Size

Mar.10

5:11 PM ET

Monday, 10 Mar 2008

One Giant Leap for MannKind

Posted By:Mike Huckman

Sectors:Insurance | Health Care Equipment and Services | Health Care | Pharmaceuticals

Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.

Although Alkermes could presumably find another corporate partner to try to rescue its "AIR Insulin" product, MannKind [MNKD Loading... () ] is the only company left still actively developing an inhalable form of diabetic insulin. And so this afternoon, MannKind put out a press release with the header, "MannKind Corporation Response to Recent Market Events", reaffirming its commitment to the device. "MannKind is absolutely commited to the continued development of its lead development product, Technosphere Insulin," the statement says.

The release goes on in detail about the product's safety and efficacy. The company is testing Technosphere on more than 5,000 people and more than 2,000 of them are in a two-year study to specifically measure the impact, if any, on lung function.

For Investors ...

Mr. Mann is putting his money where his mouth is and has reportedly invested about a billion dollars from his own bank account in the device. And the company says it has the wherewithal to see it through.

"Currently, MannKind has sufficient financial resources to fund these programs and others (Technosphere and other development pipeline products) through the end of 2009."

And despite the fact that drug giants Lilly [LLY Loading... () ] , Pfizer [PFE Loading... () ] and NovoNordisk [NVO Loading... () ] have all recently gotten out of the inhalable insulin business the release says: "It is MannKind's intention to bring these treatments to patients in collaboration with a leading pharmaceutical partner who shares a commitment to improving the lives of people with diabetes and who understands the difference between MannKind's products and other diabetes therapies on the market today."